StockData
Tonix Pharmaceuticals Holding Corp. logo

Tonix Pharmaceuticals Holding Corp. (TNXP) company profile

TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3083% below fair value
$2.94+0.06 (+2.08%)

Close on Nov 17, 2026Market cap $50.42MP/E –Yield –

About Tonix Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company that commercializes and develops therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases. Its commercial product portfolio features TONMYA, a sublingual tablet formulation for treating fibromyalgia in adults, as well as Zembrace SymTouch and Tosymra, both indicated for the treatment of acute migraine. The company's development pipeline encompasses multiple clinical- and preclinical-stage candidates targeting indications such as acute stress disorder, major depressive disorder, organ transplant rejection, cocaine intoxication, and Prader-Willi syndrome.

Tonix markets and distributes its commercial treatments within the United States through internal and contracted sales organizations, digital channels, and national and specialty distributors. The company's principal executive office is situated in Berkeley Heights, New Jersey.

Summary of the business section of Tonix Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Tonix Pharmaceuticals Holding Corp.
Headquarters
Berkeley Heights, NJ
Address
200 Connell Drive, Suite 3100 07922
Phone
(212) 980-9155
Employees
142, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Nevada
Fiscal year ends
December 31
Auditor
EisnerAmper LLP, Iselin, New Jersey

Stock & identifiers

Ticker
TNXP
Exchange
Nasdaq
IPO date
May 10, 2012
Shares outstanding
17M, Aug 7, 2026
Public float
$271.37M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-100 reverse, Feb 5, 2025; 1-for-32 reverse, Jun 10, 2024; 1-for-31.5 reverse, Aug 8, 2022; 1-for-32 reverse, May 17, 2022; 1-for-10 reverse, Nov 1, 2019; 1-for-10 reverse, Nov 28, 2018; 1-for-10 reverse, Mar 17, 2017; 1-for-20 reverse, May 1, 2013
SEC CIK
1430306
CUSIP
890260839
ISIN
US8902608392
FIGI
BBG000LG8XM5
Share class FIGI
BBG001T49NZ9
LEI
529900ACPKP9QW20GX48
EIN
26-1434750

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Seth LedermanChief Executive Officer, Director36,007
Thomas EngleseChief Commercial Officer694
Bradley SaengerChief Financial Officer2,154
Siobhan FogartyChief Technology Officer1
Gregory M. SullivanChief Medical Officer0
Jessica Edgar MorrisChief Operating Officer0
Richard H. BaggerDirector1,000
Carolyn E. TaylorDirector1,833
Richard Newcomb StillwellDirector5,000
James Randolph Hunter JrDirector–
Adeoye Y. OlukotunDirector0
Margaret Smith BellDirector0
David L. GrangeDirector–
James TrecoDirector250

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.92M$4.59M$1.20M$0–
FY2024$1.81M$1.06M$886.72K$0–
FY2023$2.05M$647.04K$928.50K$1–
FY2022$4.58M-$711.46K$1.37M$3–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsTotalvs. prior year
Seth Lederman
Chief Executive Officer
$702.00K$596.70K$1.87M$3.17M+75%
Jessica Morris
Chief Operations Officer
$522.91K$261.45K$441.91K$1.23M+38%
Bradley Saenger
Chief Financial Officer
$502.94K$251.45K$389.12K$1.14M+35%
Gregory Sullivan
Chief Medical Officer
$519.17K$259.60K$437.77K$1.22M+32%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of March 12, 2026, we had 142 full-time employees, of whom 29 hold M.D.”

Corporate history

Events identified from SEC filings

DateEventDetails
Mar 18, 2026Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 15, 2024Late filingNotification of late filing
Aug 9, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 20, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 3, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 4, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 28, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 4, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 7, 2021Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 2, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 22, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 14, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 30, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 24, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 31, 2017Late filingNotification of late filing
Oct 21, 2016Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 14, 2013Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 23, 2013ListingRegistration of securities on an exchange (Form 8-A)
Apr 3, 2012Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 3, 2012Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 27, 2011Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 27, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 17, 2011Name changeName changed from TAMANDARE EXPLORATIONS INC. to Tonix Pharmaceuticals Holding Corp.
Oct 14, 2011Auditor changeChange in certifying accountant (8-K Item 4.01)
Oct 14, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)

See a number that looks wrong?